Skye Bioscience, Inc. balance sheet SKYE

Annual Quarterly

As of Jun 30, 2026, Skye Bioscience, Inc. had total assets of $11.0 million and total liabilities of $11.5 million. Total assets were down 78.8% from a year earlier. Stockholders' equity was negative, at -$497,307, because liabilities exceed assets. It held $10.1 million in cash and investments against $35,696 of total debt, net cash of $10.0 million. The current ratio, current assets divided by current liabilities, was 0.95.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Assets
Cash
8
-66.2%
8
-82.4%
6
-91.4%
18
-72.6%
24
-67.8%
46
-44.3%
68
67
+1215.0%
Short-term investments
2
-91.9%
9
-30.0%
20
17
25
13
—
—
Cash and investments
10
-79.3%
17
-71.1%
26
-62.4%
35
-47.6%
49
-34.5%
59
-28.9%
68
67
+1215.0%
Total current assets
11
-78.3%
19
-70.5%
27
-61.7%
40
-50.0%
51
-41.9%
63
-33.4%
71
+507.9%
80
+422.1%
Property and equipment, net
0
-97.2%
1
-42.0%
1
-37.3%
1
-31.8%
1
+2454.1%
1
+3515.0%
1
+3210.7%
2
+2643.5%
Total assets
11
-78.8%
19
-70.0%
28
-61.1%
41
-49.3%
52
-40.2%
65
-31.7%
73
+509.4%
82
+422.5%
Liabilities and equity
Accounts payable
4
+32.8%
4
+129.7%
2
3
+262.2%
3
+198.5%
2
+56.5%
—
1
-52.2%
Total current liabilities
12
+38.7%
10
+95.6%
8
+89.1%
8
+48.8%
8
-42.0%
5
-66.3%
4
-68.8%
6
-59.0%
Total liabilities
12
+35.9%
10
+87.7%
8
+79.7%
8
+48.1%
8
-41.3%
6
-65.3%
5
-67.2%
6
-58.8%
Stockholders' equity
-0
-101.1%
9
-84.8%
20
-70.6%
33
-56.7%
44
-40.0%
59
-24.9%
68
+3296.9%
76
+4371.5%
Debt
Lease liabilities
0
-90.3%
0
-85.2%
0
-39.9%
0
+68.5%
0
+75.8%
0
+82.0%
0
+87.3%
0
-26.3%
Total debt
0
-90.3%
0
-85.2%
0
-39.9%
0
+68.5%
0
+75.8%
0
+82.0%
0
+87.3%
0
-26.3%
Net cash
10
-79.2%
17
-71.0%
25
-62.5%
35
-47.9%
48
-34.8%
59
-29.2%
68
67
+1281.2%
Ratios
Current ratio
0.95x
1.78x
3.30x
4.77x
6.09x
11.85x
16.32x
14.19x
Debt to equity
—
0.01x
0.01x
0.01x
0.01x
0.01x
0.01x
0.00x
Return on equity
—
-636.18%
-279.29%
-156.01%
-97.02%
-55.11%
-38.98%
-28.02%
Return on assets
-457.62%
-295.27%
-197.52%
-123.97%
-81.24%
-50.39%
-36.51%
-26.05%
Book value per share
-0.01
0.26
0.60
1.06
1.41
1.91
2.20
2.50
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SKYE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1516551
Former names
Emerald Bioscience, Inc. (until Jan 7, 2021); Nemus Bioscience, Inc. (until Mar 14, 2019); LOAD GUARD LOGISTICS, INC. (until Oct 30, 2014); LOAD GUARD TRANSPORTATION, INC. (until Nov 7, 2012)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.